Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,347 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Age-period-cohort analysis of chronic disease rates. I: Modelling approach.
Robertson C, Boyle P. Robertson C, et al. Stat Med. 1998 Jun 30;17(12):1305-23. doi: 10.1002/(sici)1097-0258(19980630)17:12<1305::aid-sim853>3.0.co;2-w. Stat Med. 1998. PMID: 9682322 Review.
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A; Italian Tamoxifen Study Group. Veronesi U, et al. J Natl Cancer Inst. 2007 May 2;99(9):727-37. doi: 10.1093/jnci/djk154. J Natl Cancer Inst. 2007. PMID: 17470740 Clinical Trial.
Epidemiology of colorectal cancer.
Boyle P, Leon ME. Boyle P, et al. Br Med Bull. 2002;64:1-25. doi: 10.1093/bmb/64.1.1. Br Med Bull. 2002. PMID: 12421722 Review.
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P; Italian Tamoxifen Study Group. Veronesi U, et al. J Natl Cancer Inst. 2003 Jan 15;95(2):160-5. doi: 10.1093/jnci/95.2.160. J Natl Cancer Inst. 2003. PMID: 12529349 Clinical Trial.
Tamoxifen administered to women in the high-risk group showed statistically significantly reduced incidence of breast cancer (tamoxifen, 3 and placebo, 15; P =.003), but no such effect was seen in the low-risk group (tamoxifen, 31 and placebo, 30; P =.89). The posit …
Tamoxifen administered to women in the high-risk group showed statistically significantly reduced incidence of breast cancer (tamoxifen, 3 a …
Breast cancer.
Veronesi U, Goldhirsch A, Boyle P, Orecchia R, Viale G. Veronesi U, et al. Discov Med. 2005 Jun;5(27):271-7. Discov Med. 2005. PMID: 20704887
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.
Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U; Italian Tamoxifen Study Group. Decensi A, et al. Circulation. 2005 Feb 8;111(5):650-6. doi: 10.1161/01.CIR.0000154545.84124.AC. Circulation. 2005. PMID: 15699284 Clinical Trial.
Of the 685 women with a CHD risk score > or =5 who entered the trial, 1 in the placebo arm and 13 in the tamoxifen arm developed VTE (log-rank P=0.0013). ...
Of the 685 women with a CHD risk score > or =5 who entered the trial, 1 in the placebo arm and 13 in the tamoxifen arm developed VTE (log …
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, Melchi CF. Gandini S, et al. Eur J Cancer. 2005 Jan;41(1):45-60. doi: 10.1016/j.ejca.2004.10.016. Eur J Cancer. 2005. PMID: 15617990 Review.
For chronic sun exposure, inclusion of controls with dermatological diseases and latitude resulted in significantly different data (P = 0.05 and 0.031, respectively). Latitude was also shown to be important (P = 0.031) for a history of sunburn; studies conducted at …
For chronic sun exposure, inclusion of controls with dermatological diseases and latitude resulted in significantly different data (P
Breast cancer.
Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Veronesi U, et al. Lancet. 2005 May 14-20;365(9472):1727-41. doi: 10.1016/S0140-6736(05)66546-4. Lancet. 2005. PMID: 15894099 Review.
Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, Melchi CF. Gandini S, et al. Eur J Cancer. 2005 Jan;41(1):28-44. doi: 10.1016/j.ejca.2004.10.015. Eur J Cancer. 2005. PMID: 15617989 Review.
ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer.
Severi G, Giles GG, Southey MC, Tesoriero A, Tilley W, Neufing P, Morris H, English DR, McCredie MR, Boyle P, Hopper JL. Severi G, et al. J Natl Cancer Inst. 2003 Jun 4;95(11):818-24. doi: 10.1093/jnci/95.11.818. J Natl Cancer Inst. 2003. PMID: 12783937
Among control subjects, there were no statistically significant associations between genotype frequencies and PSA level for either polymorphism (both P>.4). ...
Among control subjects, there were no statistically significant associations between genotype frequencies and PSA level for either polymorph …
1,347 results
Jump to page
Feedback